Canada · Delayed Price · Currency is CAD WELL Health Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong revenue growth, margin expansion, and early achievement of key profitability milestones, driven by acquisitions and tech enablement. Guidance for 2026 was raised, with WELLSTAR's public listing and strategic M&A supporting future growth.
-
Q1 2026 saw 25% revenue growth and 56% adjusted EBITDA growth, with Canadian clinics and technology platforms driving strong results. Guidance for 2026 was reaffirmed, targeting up to CAD 1.65 billion in revenue and significant margin expansion, supported by robust M&A and AI initiatives.
Fiscal Year 2025
-
Annual revenue grew 52% to CAD 1.4 billion, with record Adjusted EBITDA and strong free cash flow. Canadian clinics and technology segments drove growth, while U.S. asset divestitures and expanded credit facilities position the company for continued M&A and margin expansion.
-
Q3 2025 saw record revenue and EBITDA, driven by strong Canadian clinics, WELLSTAR, and HealWell performance. Guidance for 2025 is reaffirmed, with a robust M&A pipeline and ongoing US asset divestitures expected to further enhance growth.
-
Record Q2 2025 results with revenue up 57% and adjusted EBITDA up 231% year-over-year, driven by strong Canadian Clinics, Wellstar, and HEALWELL AI performance. Guidance for 2025 revenue and adjusted EBITDA was raised, with a robust M&A pipeline and ongoing U.S. asset divestitures.
-
Record Q1 2025 revenue and EBITDA growth were driven by Canadian operations and strategic acquisitions, while the company accelerates its exit from U.S. care delivery to focus capital on expanding its Canadian clinic network and technology platforms. Guidance for 2025 remains strong, with significant M&A activity and share buybacks planned.
Fiscal Year 2024
-
Record 2024 revenue and net income were achieved despite significant IFRS-driven revenue deferrals, with strong Canadian growth and robust M&A activity. 2025 guidance projects record revenue and EBITDA, driven by deferred revenue recognition, HEALWELL consolidation, and continued Canadian expansion.
-
Record Q3 results with revenue up 23% and Adjusted EBITDA up 16% year-over-year, driven by strong organic growth in both Canadian and U.S. segments. Raised 2024 revenue guidance to CAD 985–995 million, with robust M&A pipeline and continued margin improvements.
-
Q2 2024 saw 42% revenue growth and record net income, with strong performance across all segments and improved guidance for the year. Strategic initiatives include potential spin-outs, divestments, and major AI partnerships, while dilution and leverage continue to decline.
-
The meeting confirmed quorum, set the board at six directors, and approved all motions via electronic voting. An in-person investor day is scheduled for June 18 in Toronto, with recordings to be made available online.